<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33838757</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>07</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1474-547X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>397</Volume>
            <Issue>10282</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Apr</Month>
              <Day>10</Day>
            </PubDate>
          </JournalIssue>
          <Title>Lancet (London, England)</Title>
          <ISOAbbreviation>Lancet</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.</ArticleTitle>
        <Pagination>
          <StartPage>1363</StartPage>
          <EndPage>1374</EndPage>
          <MedlinePgn>1363-1374</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(21)00247-6</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0140-6736(21)00247-6</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Levetiracetam and zonisamide are licensed as monotherapy for patients with focal epilepsy, but there is uncertainty as to whether they should be recommended as first-line treatments because of insufficient evidence of clinical effectiveness and cost-effectiveness. We aimed to assess the long-term clinical effectiveness and cost-effectiveness of levetiracetam and zonisamide compared with lamotrigine in people with newly diagnosed focal epilepsy.</AbstractText>
          <AbstractText Label="METHODS">This randomised, open-label, controlled trial compared levetiracetam and zonisamide with lamotrigine as first-line treatment for patients with newly diagnosed focal epilepsy. Adult and paediatric neurology services across the UK recruited participants aged 5 years or older (with no upper age limit) with two or more unprovoked focal seizures. Participants were randomly allocated (1:1:1) using a minimisation programme with a random element utilising factor to receive lamotrigine, levetiracetam, or zonisamide. Participants and investigators were not masked and were aware of treatment allocation. SANAD II was designed to assess non-inferiority of both levetiracetam and zonisamide to lamotrigine for the primary outcome of time to 12-month remission. Anti-seizure medications were taken orally and for participants aged 12 years or older the initial advised maintenance doses were lamotrigine 50 mg (morning) and 100 mg (evening), levetiracetam 500 mg twice per day, and zonisamide 100 mg twice per day. For children aged between 5 and 12 years the initial daily maintenance doses advised were lamotrigine 1·5 mg/kg twice per day, levetiracetam 20 mg/kg twice per day, and zonisamide 2·5 mg/kg twice per day. All participants were included in the intention-to-treat (ITT) analysis. The per-protocol (PP) analysis excluded participants with major protocol deviations and those who were subsequently diagnosed as not having epilepsy. Safety analysis included all participants who received one dose of any study drug. The non-inferiority limit was a hazard ratio (HR) of 1·329, which equates to an absolute difference of 10%. A HR greater than 1 indicated that an event was more likely on lamotrigine. The trial is registered with the ISRCTN registry, 30294119 (EudraCt number: 2012-001884-64).</AbstractText>
          <AbstractText Label="FINDINGS">990 participants were recruited between May 2, 2013, and June 20, 2017, and followed up for a further 2 years. Patients were randomly assigned to receive lamotrigine (n=330), levetiracetam (n=332), or zonisamide (n=328). The ITT analysis included all participants and the PP analysis included 324 participants randomly assigned to lamotrigine, 320 participants randomly assigned to levetiracetam, and 315 participants randomly assigned to zonisamide. Levetiracetam did not meet the criteria for non-inferiority in the ITT analysis of time to 12-month remission versus lamotrigine (HR 1·18; 97·5% CI 0·95-1·47) but zonisamide did meet the criteria for non-inferiority in the ITT analysis versus lamotrigine (1·03; 0·83-1·28). The PP analysis showed that 12-month remission was superior with lamotrigine than both levetiracetam (HR 1·32 [97·5% CI 1·05 to 1·66]) and zonisamide (HR 1·37 [1·08-1·73]). There were 37 deaths during the trial. Adverse reactions were reported by 108 (33%) participants who started lamotrigine, 144 (44%) participants who started levetiracetam, and 146 (45%) participants who started zonisamide. Lamotrigine was superior in the cost-utility analysis, with a higher net health benefit of 1·403 QALYs (97·5% central range 1·319-1·458) compared with 1·222 (1·110-1·283) for levetiracetam and 1·232 (1·112, 1·307) for zonisamide at a cost-effectiveness threshold of £20 000 per QALY. Cost-effectiveness was based on differences between treatment groups in costs and QALYs.</AbstractText>
          <AbstractText Label="INTERPRETATION">These findings do not support the use of levetiracetam or zonisamide as first-line treatments for patients with focal epilepsy. Lamotrigine should remain a first-line treatment for patients with focal epilepsy and should be the standard treatment in future trials.</AbstractText>
          <AbstractText Label="FUNDING">National Institute for Health Research Health Technology Assessment programme.</AbstractText>
          <CopyrightInformation>Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Marson</LastName>
            <ForeName>Anthony</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK. Electronic address: a.g.marson@liverpool.ac.uk.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Burnside</LastName>
            <ForeName>Girvan</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Health Data Science, University of Liverpool, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Appleton</LastName>
            <ForeName>Richard</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>The Roald Dahl EEG Unit, Alder Hey Children's Health Park, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Smith</LastName>
            <ForeName>Dave</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>The Walton Centre NHS Foundation Trust, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Leach</LastName>
            <ForeName>John Paul</ForeName>
            <Initials>JP</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine, University of Glasgow, Glasgow, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sills</LastName>
            <ForeName>Graeme</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tudur-Smith</LastName>
            <ForeName>Catrin</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Health Data Science, University of Liverpool, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Plumpton</LastName>
            <ForeName>Catrin</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Centre for Health Economics and Medicines Evaluation, Bangor University, Bangor, Wales, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hughes</LastName>
            <ForeName>Dyfrig A</ForeName>
            <Initials>DA</Initials>
            <AffiliationInfo>
              <Affiliation>Centre for Health Economics and Medicines Evaluation, Bangor University, Bangor, Wales, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Williamson</LastName>
            <ForeName>Paula</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Health Data Science, University of Liverpool, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Baker</LastName>
            <ForeName>Gus A</ForeName>
            <Initials>GA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Balabanova</LastName>
            <ForeName>Silviya</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Taylor</LastName>
            <ForeName>Claire</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brown</LastName>
            <ForeName>Richard</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Addenbrooke's Hospital NHS Foundation Trust, Cambridge, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hindley</LastName>
            <ForeName>Dan</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Bolton NHS Foundation Trust, Royal Bolton Hospital, Lancashire, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Howell</LastName>
            <ForeName>Stephen</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Royal Hallamshire Hospital, Sheffield, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maguire</LastName>
            <ForeName>Melissa</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine, University of Leeds, Leeds, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mohanraj</LastName>
            <ForeName>Rajiv</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Salford Royal NHS Foundation Trust, Manchester, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Smith</LastName>
            <ForeName>Philip E</ForeName>
            <Initials>PE</Initials>
            <AffiliationInfo>
              <Affiliation>The Alan Richens Epilepsy Unit, University Hospital of Wales, Cardiff, Wales, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <CollectiveName>SANAD II collaborators</CollectiveName>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D017429">Clinical Trial, Phase IV</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016448">Multicenter Study</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Lancet</MedlineTA>
        <NlmUniqueID>2985213R</NlmUniqueID>
        <ISSNLinking>0140-6736</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>44YRR34555</RegistryNumber>
          <NameOfSubstance UI="D000077287">Levetiracetam</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>459384H98V</RegistryNumber>
          <NameOfSubstance UI="D000078305">Zonisamide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>U3H27498KS</RegistryNumber>
          <NameOfSubstance UI="D000077213">Lamotrigine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Lancet. 2021 Apr 10;397(10282):1327-1329</RefSource>
          <PMID Version="1">33838747</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="ErratumIn">
          <RefSource>Lancet. 2021 May 15;397(10287):1808</RefSource>
          <PMID Version="1">33992146</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>J Alzheimers Dis. 2022;85(2):527-529</RefSource>
          <PMID Version="1">34842191</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003362" MajorTopicYN="Y">Cost-Benefit Analysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004828" MajorTopicYN="N">Epilepsies, Partial</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077213" MajorTopicYN="N">Lamotrigine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077287" MajorTopicYN="N">Levetiracetam</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="Y">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000078305" MajorTopicYN="N">Zonisamide</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Declaration of interests AM reports grants from the National Institute for Health Research Health Technology Assessment, during the conduct of the study, as well as grants from UCB Pharma, outside of the submitted work. JPL reports grants from University of Liverpool during the conduct of the study; grants and personal fees from UCB Pharma; and personal fees from Eisai, Janssen CIlag Pharmaceuticals, GW Pharmaceuticals, GSK Pharma, outside of the submitted work. GS reports personal fees from UCB Pharma, Eisai, Arvelle Therapeutics GmbH, outside of the submitted work. CP reports grants from National Institute for Health and Care Research Health Technology Assessment Programme during the conduct of this study. CT reports grants from University of Liverpool during the conduct of the study. DH reports grants from National Institute for Health Research Health Technology Assessment Programme during the conduct of the study. RM reports personal fees from UCB Pharma and grants from UCB Pharma and Sanofi, outside of the submitted work. PES is a member of the NICE Panel for Epilepsy guideline 2021 and is an editor of the journal Practical Neurology. All other authors declare no competing interests.</CoiStatement>
      <InvestigatorList>
        <Investigator ValidYN="Y">
          <LastName>Lanyon</LastName>
          <ForeName>Karen</ForeName>
          <Initials>K</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Manford</LastName>
          <ForeName>Mark</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Chitre</LastName>
          <ForeName>Manali</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Parker</LastName>
          <ForeName>Alasdair</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Swiderska</LastName>
          <ForeName>Nina</ForeName>
          <Initials>N</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Appleton</LastName>
          <ForeName>Richard</ForeName>
          <Initials>R</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Pauling</LastName>
          <ForeName>James</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Hughes</LastName>
          <ForeName>Adrian</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Gupta</LastName>
          <ForeName>Rajat</ForeName>
          <Initials>R</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Hanif</LastName>
          <ForeName>Sadia</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Awadh</LastName>
          <ForeName>Mostafa</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Ragunathan</LastName>
          <ForeName>Sharmini</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Cable</LastName>
          <ForeName>Nicola</ForeName>
          <Initials>N</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Cooper</LastName>
          <ForeName>Paul</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Hindley</LastName>
          <ForeName>Daniel</ForeName>
          <Initials>D</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Rakshi</LastName>
          <ForeName>Karl</ForeName>
          <Initials>K</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Molloy</LastName>
          <ForeName>Sophie</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Reuber</LastName>
          <ForeName>Markus</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Ayonrinde</LastName>
          <ForeName>Kunle</ForeName>
          <Initials>K</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Wilson</LastName>
          <ForeName>Martin</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Saladi</LastName>
          <ForeName>Satyanarayana</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Gibb</LastName>
          <ForeName>John</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Funston</LastName>
          <ForeName>Lesley-Ann</ForeName>
          <Initials>LA</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Cassidy</LastName>
          <ForeName>Damhait</ForeName>
          <Initials>D</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Boyd</LastName>
          <ForeName>Jonathan</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Ratnayaka</LastName>
          <ForeName>Mal</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Faza</LastName>
          <ForeName>Hani</ForeName>
          <Initials>H</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Sadler</LastName>
          <ForeName>Martin</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Al-Moasseb</LastName>
          <ForeName>Hassan</ForeName>
          <Initials>H</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Galtrey</LastName>
          <ForeName>Clare</ForeName>
          <Initials>C</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Wren</LastName>
          <ForeName>Damien</ForeName>
          <Initials>D</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Olabi</LastName>
          <ForeName>Anas</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Fuller</LastName>
          <ForeName>Geraint</ForeName>
          <Initials>G</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Khan</LastName>
          <ForeName>Muhammed</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Kallappa</LastName>
          <ForeName>Chetana</ForeName>
          <Initials>C</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Chinthapalli</LastName>
          <ForeName>Ravi</ForeName>
          <Initials>R</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Aji</LastName>
          <ForeName>Baba</ForeName>
          <Initials>B</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Davies</LastName>
          <ForeName>Rhys</ForeName>
          <Initials>R</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Foster</LastName>
          <ForeName>Kathryn</ForeName>
          <Initials>K</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Hitiris</LastName>
          <ForeName>Nikolas</ForeName>
          <Initials>N</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Maguire</LastName>
          <ForeName>Melissa</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Hussain</LastName>
          <ForeName>Nahin</ForeName>
          <Initials>N</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Dowson</LastName>
          <ForeName>Simon</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Ellison</LastName>
          <ForeName>Julie</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Sharrack</LastName>
          <ForeName>Basil</ForeName>
          <Initials>B</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Gandhi</LastName>
          <ForeName>Vandna</ForeName>
          <Initials>V</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Powell</LastName>
          <ForeName>Rob</ForeName>
          <Initials>R</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Tittensor</LastName>
          <ForeName>Phil</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Summers</LastName>
          <ForeName>Beatrice</ForeName>
          <Initials>B</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Shashikiran</LastName>
          <ForeName>Sastry</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Dison</LastName>
          <ForeName>Penelope J</ForeName>
          <Initials>PJ</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Samarasekera</LastName>
          <ForeName>Shanika</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>McCorry</LastName>
          <ForeName>Doug</ForeName>
          <Initials>D</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>White</LastName>
          <ForeName>Kathleen</ForeName>
          <Initials>K</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Nithi</LastName>
          <ForeName>Kannan</ForeName>
          <Initials>K</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Richardson</LastName>
          <ForeName>Martin</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Brown</LastName>
          <ForeName>Richard</ForeName>
          <Initials>R</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Page</LastName>
          <ForeName>Rupert</ForeName>
          <Initials>R</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Deekollu</LastName>
          <ForeName>David</ForeName>
          <Initials>D</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Slaght</LastName>
          <ForeName>Sean</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Warriner</LastName>
          <ForeName>Stephen</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Ahmed</LastName>
          <ForeName>Mansoor</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Chaudhuri</LastName>
          <ForeName>Abhijit</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Chow</LastName>
          <ForeName>Gabriel</ForeName>
          <Initials>G</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Artal</LastName>
          <ForeName>Javier</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Kucinskiene</LastName>
          <ForeName>Danute</ForeName>
          <Initials>D</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Sreenivasa</LastName>
          <ForeName>Harish</ForeName>
          <Initials>H</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Velmurugan</LastName>
          <ForeName>Singara</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Zipitis</LastName>
          <ForeName>Christos S</ForeName>
          <Initials>CS</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>McLean</LastName>
          <ForeName>Brendan</ForeName>
          <Initials>B</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Lal</LastName>
          <ForeName>Vaithianathar</ForeName>
          <Initials>V</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Gregoriou</LastName>
          <ForeName>Angelous</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Maddison</LastName>
          <ForeName>Paul</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Pickersgill</LastName>
          <ForeName>Trevor</ForeName>
          <Initials>T</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Anderson</LastName>
          <ForeName>Joseph</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Lawthom</LastName>
          <ForeName>Charlotte</ForeName>
          <Initials>C</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Howell</LastName>
          <ForeName>Stephen</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Whitlingum</LastName>
          <ForeName>Gabriel</ForeName>
          <Initials>G</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Rakowicz</LastName>
          <ForeName>Wojtek</ForeName>
          <Initials>W</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Kinton</LastName>
          <ForeName>Lucy</ForeName>
          <Initials>L</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>McLellan</LastName>
          <ForeName>Alisa</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Vora</LastName>
          <ForeName>Nitish</ForeName>
          <Initials>N</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Zuberi</LastName>
          <ForeName>Sameer</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Kelso</LastName>
          <ForeName>Andrew</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Hughes</LastName>
          <ForeName>Imelda</ForeName>
          <Initials>I</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Martland</LastName>
          <ForeName>John</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Emsley</LastName>
          <ForeName>Hedley</ForeName>
          <Initials>H</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>de Goede</LastName>
          <ForeName>Christian</ForeName>
          <Initials>C</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Singh</LastName>
          <ForeName>R P</ForeName>
          <Initials>RP</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Moor</LastName>
          <ForeName>Carl-Christian</ForeName>
          <Initials>CC</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Aram</LastName>
          <ForeName>Julia</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Mohanraj</LastName>
          <ForeName>Rajiv</ForeName>
          <Initials>R</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Sakthivel</LastName>
          <ForeName>Kumar</ForeName>
          <Initials>K</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Nelapatla</LastName>
          <ForeName>Suresh</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Rittey</LastName>
          <ForeName>Chris</ForeName>
          <Initials>C</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Pinto</LastName>
          <ForeName>Ashwin</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Leach</LastName>
          <ForeName>John Paul</ForeName>
          <Initials>JP</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Cock</LastName>
          <ForeName>Hannah</ForeName>
          <Initials>H</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Richardson</LastName>
          <ForeName>Anna</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Houston</LastName>
          <ForeName>Erika</ForeName>
          <Initials>E</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Cooper</LastName>
          <ForeName>Christopher</ForeName>
          <Initials>C</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Lawson</LastName>
          <ForeName>Geoff</ForeName>
          <Initials>G</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Massarano</LastName>
          <ForeName>Albert</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Burness</LastName>
          <ForeName>Christine</ForeName>
          <Initials>C</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Marson</LastName>
          <ForeName>Anthony</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Smith</LastName>
          <ForeName>Dave</ForeName>
          <Initials>D</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Wieshmann</LastName>
          <ForeName>Udo</ForeName>
          <Initials>U</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Dey</LastName>
          <ForeName>Indranil</ForeName>
          <Initials>I</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Sivakumar</LastName>
          <ForeName>Puthuval</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Yeung</LastName>
          <ForeName>Lap-Kong</ForeName>
          <Initials>LK</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Smith</LastName>
          <ForeName>Philip</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Bentur</LastName>
          <ForeName>Hemalata</ForeName>
          <Initials>H</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Heafield</LastName>
          <ForeName>Tom</ForeName>
          <Initials>T</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Mathew</LastName>
          <ForeName>Anna</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Smith</LastName>
          <ForeName>David</ForeName>
          <Initials>D</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Jauhari</LastName>
          <ForeName>Praveen</ForeName>
          <Initials>P</Initials>
        </Investigator>
      </InvestigatorList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>11</Day>
          <Hour>20</Hour>
          <Minute>18</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33838757</ArticleId>
        <ArticleId IdType="pmc">PMC8047799</ArticleId>
        <ArticleId IdType="doi">10.1016/S0140-6736(21)00247-6</ArticleId>
        <ArticleId IdType="pii">S0140-6736(21)00247-6</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Hesdorffer DC, Logroscino G, Benn EK, Katri N, Cascino G, Hauser WA. Estimating risk for developing epilepsy: a population-based study in Rochester, Minnesota. Neurology. 2011;76:23–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3032191</ArticleId>
            <ArticleId IdType="pubmed">21205691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fiest KM, Sauro KM, Wiebe S. Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies. Neurology. 2017;88:296–303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5272794</ArticleId>
            <ArticleId IdType="pubmed">27986877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holland P, Lane S, Whitehead M, Marson AG, Jacoby A. Labor market participation following onset of seizures and early epilepsy: findings from a UK cohort. Epilepsia. 2009;50:1030–1039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19178562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schachter SC. Quality of life for patients with epilepsy is determined by more than seizure control: the role of psychosocial factors. Expert Rev Neurother. 2006;6:111–118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16466318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia. 1981;22:489–501. No author.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6790275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia. 1989;30 No author.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2502382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scheffer IE, Berkovic S, Capovilla G. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58:512–521.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5386840</ArticleId>
            <ArticleId IdType="pubmed">28276062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonnett L, Smith CT, Smith D, Williamson P, Chadwick D, Marson AG. Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial. Lancet Neurol. 2012;11:331–340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22377180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>National Institute for Health and Clinical Excellence  Epilepsies: diagnosis and management. 2012. https://www.nice.org.uk/guidance/cg137</Citation>
        </Reference>
        <Reference>
          <Citation>Marson AG, Al-Kharusi AM, Alwaidh M. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369:1000–1015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2080688</ArticleId>
            <ArticleId IdType="pubmed">17382827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology. 2007;68:402–408.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17283312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trinka E, Marson AG, Van Paesschen W. KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy. J Neurol Neurosurg Psychiatry. 2013;84:1138–1147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22933814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seino M. Review of zonisamide development in Japan. Seizure. 2004;13(suppl 1):S2–S4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15511683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baulac M, Brodie MJ, Patten A, Segieth J, Giorgi L. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol. 2012;11:579–588.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22683226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacoby A, Baker G, Smith D, Dewey M, Chadwick D. Measuring the impact of epilepsy: the development of a novel scale. Epilepsy Res. 1993;16:83–88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8243442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ravens-Sieberer U, Bullinger M. Assessing health-related quality of life in chronically ill children with the German KINDL: first psychometric and content analytical results. Qual Life Res. 1998;7:399–407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9691720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cramer JA, Westbrook LE, Devinsky O, Perrine K, Glassman MB, Camfield C. Development of the Quality of Life in Epilepsy Inventory for Adolescents: the QOLIE-AD-48. Epilepsia. 1999;40:1114–1121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10448825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.</Citation>
        </Reference>
        <Reference>
          <Citation>Williamson PR, Smith CT, Sander JW, Marson AG. Importance of competing risks in the analysis of anti-epileptic drug failure. Trials. 2007;8:12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1853111</ArticleId>
            <ArticleId IdType="pubmed">17394663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>National Institute for Health and Care Excellence  Guide to the Methods of Technology Appraisal. 2013. https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781</Citation>
        </Reference>
        <Reference>
          <Citation>Gabrio A, Mason AJ, Baio G. Handling missing data in within-trial cost-effectiveness analysis: a review with future recommendations. Pharmacoeconom Open. 2017;1:79–97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5691848</ArticleId>
            <ArticleId IdType="pubmed">29442336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hill H, Rowen D, Pennington B, Wong R, Wailoo A. A review of the methods used to generate utility values in NICE technology assessments for children and adolescents. Value Health. 2020;23:907–917.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32762993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chadwick D. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy. Epilepsia. 1998;39:799–803.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9670910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clark TG, Altman DG, De Stavola BL. Quantification of the completeness of follow-up. Lancet. 2002;359:1309–1310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11965278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mihaylova B, Briggs A, O'Hagan A, Thompson SG. Review of statistical methods for analysing healthcare resources and costs. Health Econ. 2011;20:897–916.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3470917</ArticleId>
            <ArticleId IdType="pubmed">20799344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mulhern B, Rowen D, Jacoby A. The development of a QALY measure for epilepsy: NEWQOL-6D. Epilepsy Behav. 2012;24:36–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22503427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>American Epilepsy Society  Drug alerts and FDA news. 2020. https://www.aesnet.org/clinical_resources/treatments/drug_alerts_fda_news</Citation>
        </Reference>
        <Reference>
          <Citation>Ramos-Goñi JMOM, Oppe M, Stolk E. International valuation protocol for the EQ-5D-Y-3L. Pharmacoeconomics. 2020;38:653–663.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32297224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>European Medicines Agency  Guideline on clinical investigation of medicinal products in the treatment of epileptic disorders. 2010. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-epileptic-disorders-revision-2_en.pdf</Citation>
        </Reference>
        <Reference>
          <Citation>Perucca E. From clinical trials of antiepileptic drugs to treatment. Epilepsia Open. 2018;3:220–230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6293126</ArticleId>
            <ArticleId IdType="pubmed">30564781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nevitt SJ, Sudell M, Weston J, Tudur Smith C, Marson AG. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database Syst Rev. 2017;6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6481892</ArticleId>
            <ArticleId IdType="pubmed">28661008</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
